Format

Send to

Choose Destination
Pharmacol Ther. 2017 Jun;174:22-26. doi: 10.1016/j.pharmthera.2017.02.003. Epub 2017 Feb 3.

Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis.

Author information

1
Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA.
2
Center for Noninvasive Diagnostics, Translational Genomics Research Institute, Phoenix, AZ, USA; Mayo Clinic Center for Individualized Medicine, Scottsdale, AZ, USA. Electronic address: mmurtaza@tgen.org.

Abstract

Circulating tumor DNA analysis has emerged as a potential noninvasive alternative to tissue biopsies for tumor genotyping in patients with metastatic cancer. This is particularly attractive in cases where tissue biopsies are contraindicated or repeat genotyping after progression on treatment is required. However, tissue and plasma analysis results are not always concordant and clinical interpretation of discordant results is not completely understood. Discordant results could arise due to analytical limits of assays used for tumor and plasma DNA analysis or due to low overall contribution of tumor-specific DNA in plasma. Once these factors are ruled out, tissue-plasma concordance and quantitative levels of somatic mutations in plasma can capture tumor heterogeneity. During longitudinal follow-up of patients, this feature can be leveraged to track subclonal evolution and to guide combination or sequential adaptive treatment. Here, we summarize recent results evaluating the opportunities and limitations of circulating tumor DNA analysis in the context of tumor heterogeneity and subclonal evolution in patients with advanced cancers.

KEYWORDS:

Cell-free DNA; Circulating tumor DNA; Clonal evolution; Treatment resistance; Tumor heterogeneity

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center